Cytokinetics, Inc.
(NASDAQ : CYTK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-2.13%199.081.3%$749.78m
GILDGilead Sciences, Inc.
-2.66%62.510.9%$372.82m
CELGCelgene Corporation
-1.80%93.991.3%$323.19m
ALXNAlexion Pharmaceuticals, Inc.
-6.61%115.332.0%$295.67m
ILMNIllumina, Inc.
-3.17%279.443.5%$272.03m
BIIBBiogen Inc.
-2.68%225.851.3%$258.17m
VRTXVertex Pharmaceuticals Incorporated
-2.20%180.181.9%$251.48m
EXASExact Sciences Corporation
-0.77%116.9624.1%$238.08m
REGNRegeneron Pharmaceuticals, Inc.
-2.77%286.852.6%$193.57m
AAgilent Technologies, Inc.
-3.01%69.581.6%$188.95m
SRPTSarepta Therapeutics, Inc.
-1.54%93.6114.7%$184.96m
BMRNBioMarin Pharmaceutical Inc.
-2.12%75.764.3%$97.12m
INCYIncyte Corporation
-4.27%81.912.5%$90.56m
GHDXGenomic Health, Inc.
-0.35%73.261.8%$81.69m
NBIXNeurocrine Biosciences, Inc.
0.36%97.595.0%$71.75m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.